SOLIFENACIN SUCCINATE 5mg TABLET (Soliturn 5)

Selective Antimuscarinic Treatment for Overactive Bladder (OAB)

Clinical Benefits: Managing Urinary Urgency and Frequency

Mechanism of Action: How Soliturn 5 Stabilizes Bladder Muscles

Uropair Division: Monopoly-Based Urology & Nephrology Franchise
Prescribing Information: Dosage and WHO-GMP Quality Standards

Home/Products /solifenacin-5mg-tablet

Soliturn 5 Tablet

Composition : Solifenacin (5mg)

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹330/-

Empowering Bladder Control with Precision: The Uropair Approach

Soliturn 5 (Solifenacin Succinate 5mg) represents the pinnacle of our Uropair division's commitment to specialized urological care. As a selective muscarinic M3 receptor antagonist, Soliturn 5 is specifically engineered to address the complexities of Overactive Bladder (OAB). By targeting the detrusor muscle’s stability, it provides a clinical solution for patients struggling with involuntary contractions, effectively reducing the daily burden of urinary urgency and frequenc

At Cafoli Lifecare, we understand that urology requires a higher standard of purity and efficacy. That is why Soliturn 5 is manufactured in world-class WHO-GMP certified facilities, ensuring that every tablet delivers consistent pharmacokinetic performance. For our PCD Pharma partners, Soliturn 5 offers a high-demand, monopoly-based molecule that strengthens any urology portfolio.

Key Therapeutic Indications:

  • Management of urge incontinence.

  • Reduction of increased urinary frequency (pollakisuria).

  • Treatment of urgency symptoms associated with OAB syndrome.

By integrating Soliturn 5 into your practice or distribution network, you are choosing a product backed by transparent ethical policies and the specialized expertise of the Uropair division—where nephrology and urology meet advanced pharmaceutical science.

Read More

About the Product

Empowering Bladder Control with Precision: The Uropair Approach

Soliturn 5 (Solifenacin Succinate 5mg) represents the pinnacle of our Uropair division's commitment to specialized urological care. As a selective muscarinic M3 receptor antagonist, Soliturn 5 is specifically engineered to address the complexities of Overactive Bladder (OAB). By targeting the detrusor muscle’s stability, it provides a clinical solution for patients struggling with involuntary contractions, effectively reducing the daily burden of urinary urgency and frequenc

At Cafoli Lifecare, we understand that urology requires a higher standard of purity and efficacy. That is why Soliturn 5 is manufactured in world-class WHO-GMP certified facilities, ensuring that every tablet delivers consistent pharmacokinetic performance. For our PCD Pharma partners, Soliturn 5 offers a high-demand, monopoly-based molecule that strengthens any urology portfolio.

Key Therapeutic Indications:

  • Management of urge incontinence.

  • Reduction of increased urinary frequency (pollakisuria).

  • Treatment of urgency symptoms associated with OAB syndrome.

By integrating Soliturn 5 into your practice or distribution network, you are choosing a product backed by transparent ethical policies and the specialized expertise of the Uropair division—where nephrology and urology meet advanced pharmaceutical science.

Common side effects may include dry mouth, constipation, blurred vision, and urinary retention. Consult a doctor if severe side effects occur.

Soliturn 5 Tablet is indicated for the treatment of overactive bladder syndrome with symptoms such as urinary urgency, frequency, and incontinence.

Use with caution in patients with a history of urinary retention, glaucoma, or gastrointestinal disorders. Consult your healthcare provider before use if pregnant or breastfeeding.

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation